Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00474058 · ClinicalTrials.gov registry record · Phase 3
Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 287
- Enrollment target
NCT00474058 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 287 participants.
The verdict
NCT00474058, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 287 participants
- Enrollment target
Study Summary
The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of Parkinson´s disease will be evaluated.
Interventions
- OTHER Placebo
- DRUG Rotigotine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00474058
The ClinicalTrials.gov registry entry for NCT00474058 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 287 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00474058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00474058 about?
NCT00474058 is a clinical study titled "Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine". The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease. In addition, effects of rotigotine on specific nocturnal and non-motor symptoms of P...
What is the current status of trial NCT00474058?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 287 participants. The study started on 2007-05. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00474058?
The interventions under investigation include: Placebo (OTHER), Rotigotine (DRUG).
Who is sponsoring clinical trial NCT00474058?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.